Background: Patients receiving hospice or palliative care often receive antimicrobial therapy; however the effectiveness of antimicrobial therapy for symptom management in these patients is unknown. Objective: The study's objective was to systematically review and summarize existing data on the prevalence and effectiveness of antimicrobial therapy to improve symptom burden among hospice or palliative care patients. Design: Systematic review of articles on microbial use in hospice and palliative care patients published from January 1, 2001 through June 30, 2011. Measurements: We extracted data on patients' underlying chronic condition and health care setting, study design, prevalence of antimicrobial use, whether symptom response following antimicrobial use was measured, and the method for measuring symptom response. Results: Eleven studies met our inclusion criteria in which prevalence of antimicrobial use ranged from 4% to 84%. Eight studies measured symptom response following antimicrobial therapy. Methods of symptom assessment were highly variable and ranged from clinical assessment from patients' charts to the Edmonton Symptom Assessment Scale. Symptom improvement varied by indication, and patients with urinary tract infections (two studies) appeared to experience the greatest improvement following antimicrobial therapy (range 67% to 92%). Conclusion: Limited data are available on the use of antimicrobial therapy for symptom management among patients receiving palliative or hospice care. Future studies should systematically measure symptom response and control for important confounders to provide useful data to guide antimicrobial use in this population.
Introduction
H ospice and palliative care utilization is expected to increase with the aging of the U.S. population and increases in the prevalence of chronic and/or terminal diseases including cancer, chronic obstructive pulmonary disease, and dementia. 1, 2 Hospice and palliative care patients are at high risk for infection, and we recently published data to suggest that 27% of hospice patients received antibiotics in the final week of life. 3 Despite this high prevalence, indications for antimicrobial therapy in hospice care remain unclear in a setting where death is expected and the benefits of antimicrobial therapy are not well understood. Potential negative consequences of antimicrobial use in this population include medication side effects and adverse events, necessitating use of invasive devices, increased risk of subsequent opportunistic infections, and prolongation of an undesirable dying process. 4 In addition, the use of potentially unnecessary antimicrobial therapy increases selective pressure and subsequent development of antimicrobial-resistant organisms.
In 2002, Nagy-Agren and Haley published a systematic review assessing infection management in palliative care patients with advanced cancer. 5 In that study they reported that between 60% and 72% of patients with suspected infections were treated with antibiotics; however, only one study was reported to have examined whether antibiotic use improved patients' symptoms. In the past ten years several new studies examining infection management in palliative care patients have been published. Therefore, we systematically reviewed the literature on antimicrobial use among adult patients with any diagnosis who were receiving palliative or hospice care with the objective of summarizing existing data on the use of antimicrobial therapy to improve symptom burden and the methods used to measure symptom improvement. These data are needed to guide antimicrobial therapy in this patient population.
Methods

Study identification
We queried the National Library of Medicine using the PubMed database for English-language articles published from January 1, 2001 through June 30, 2011. Limits were set to restrict the search to original research articles published in English and involving human subjects. The following search terms were used: (palliative care OR terminal care OR hospice care OR end-of-life) AND (infection OR antibiotic OR antifungal OR anti-infective). Additional studies were identified by a review of references from all retrieved articles.
Articles were included in this review if they provided data on antimicrobial use in patient populations under hospice or palliative care. We excluded studies that assessed only the use of antimicrobial wound dressings or mouthwashes as well as studies focusing strictly on pharmacokinetics of antimicrobials or environmental decontamination. Survey-based studies evaluating clinician decision making regarding antimicrobial prescription, without data on actual antimicrobials prescribing, and review articles were also excluded.
One author (J.H.R.) independently reviewed all articles and abstracts retrieved through the initial search to identify those meeting inclusion and exclusion criteria. Identified publications were further reviewed by two other authors (J.S.A. and B.N.N.). A fourth author (J.P.F.) resolved any discrepancies between reviewers. This study was determined to be exempt from institutional review board approval.
Data extraction and analysis
The following information was extracted from articles meeting the inclusion criteria: author(s), location of study, year of publication, sample size, patient population (underlying chronic condition and health care setting), study design, whether infective symptom response following antimicrobial use was reported, method for assessing symptom response, whether prophylactic antimicrobial use was reported or included in analysis, and the prevalence of antimicrobial use. Prevalence of antimicrobial use was based either on patients or infective episodes. Prevalence of antimicrobial use was calculated based on the text of the article in cases where it was not explicitly reported in order to provide a homogenous depiction of the outcome.
For studies reporting symptom response, the following additional information was extracted: definition of symptom response, indication for antimicrobial use (infection site), and results regarding symptom response. For three studies, we recalculated the proportion of patients in whom symptom improvement was observed to generate measures of effect comparable to that of the other studies. [6] [7] [8] We calculated 95% confidence intervals for sample proportions using the exact binomial method to provide precision of estimation.
Results
We identified 984 articles in the National Library of Medicine database that met the search criteria. After reviewing these articles and those that were cross-referenced, we identified 11 publications that met all study criteria and which were therefore included in our systematic review. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Characteristics of these studies are displayed in Table 1 . Sample size ranged from 70 to 1598 patients (median = 150 patients). Six of the studies were conducted in North America, 10, 11, [13] [14] [15] [16] one in Europe, 6 three in Asia, 8, 9, 12 and one in Australia. 7 Six studies were conducted in hospitals, [7] [8] [9] [10] 12, 13 two in home-based hospice programs, 15, 16 one in an inpatient hospice, 6 one in a long-term care facility, 11 and one study was conducted in multiple care settings (acute hospital, tertiary palliative care unit, and hospice).
14 Four studies were prospective 7, 13, 15, 16 and seven studies were retrospective. 6, [8] [9] [10] [11] [12] 14 Six studies included only cancer patients. 8, [12] [13] [14] [15] [16] Four studies included all primary diagnoses requiring palliative care or consult. 6, 7, 9, 10 One study included only dementia patients. 11 Only one study reported prophylaxis as an indication for antimicrobial prescription, citing use in two patients for traumatic urinary catheter insertion. 7 The remaining 10 studies reported only therapeutic antimicrobial use.
6,8-16
Prevalence of antimicrobial use
Among the six studies that only included patients with cancer, 8, [12] [13] [14] [15] [16] the prevalence of antimicrobial use in patients receiving palliative care ranged from 19% 13 to 84%. 8 Among patients with documented infective episodes, 92% 15 to 100% 13 were treated with antimicrobial therapy.
In the five studies that included all diagnoses, the prevalence of antimicrobial use varied by route of administration and indication for use.
6,7,9-11 Brabin and colleagues 6 and Clayton and colleagues 7 focused exclusively on patients who received parenteral antimicrobial therapy and reported prevalence of 9% and 4%, respectively. Chen and colleagues 9 focused specifically on fever episodes as the indication for antimicrobial therapy and observed that 85% were treated with antimicrobials. The remaining two studies by Chun and colleagues 10 and Evers and colleagues 11 reported antimicrobial use regardless of indication for use or route of administration and both observed that 53% of palliative care patients received antimicrobials.
When comparing antimicrobial use by setting of care, hospital-based studies [7] [8] [9] [10] 12, 13 reported the prevalence of antimicrobial use ranged from 4% 13 to 97.5% 12 compared to studies set in hospices, 6, 15, 16 where the reported prevalence ranged from 8.6%
6 to 37%. 15 
Studies reporting symptom response
Eight studies reported some measure of symptom response. [6] [7] [8] [9] 12, 13, 15, 16 Of these, five included only cancer patients, 8, 12, 13, 15, 16 and three included all primary diagnoses requiring palliative care. 6, 7, 9 Four of the studies were prospective 7, 13, 15, 16 and four were retrospective. 6, 8, 9, 12 Studies varied in their definitions of symptom response, as well as the extent to which they reported the specific symptoms assessed. Two studies clearly listed all symptoms assessed for response 15, 16 and one study included a partial list. 8 In the retrospective studies, medical charts were reviewed for documentation of improvement in infective symptoms. In the prospective studies, symptom response was determined by clinician assessment, sometimes supplemented by patient or caregiver assessment. 7, 13, 15, 16 Methods of assessing symptom response ranged from an ordinal scale to a validated metric. 7, 13 Clayton and colleagues used a rating of ''helpful,'' ''unhelpful,'' and ''other,'' which was specifically defined and based primarily upon resolution of infective symptoms. 7 Mirhosseini and colleagues modified the Edmonton Symptom Assessment Scale, a validated metric for quantifying symptom intensity, to include symptoms of infection identified by patients and physicians. 13 This study also used a physician's ''global assessment of the patient's condition.'' 13 
Efficacy of antimicrobial treatment
Improvement in the patient's condition and/or infectionrelated symptoms (for all infection sites) following administration of antimicrobials by any route varied from 21.4% 8 (95% CI, 13.2% to 31.7%) of cases to 56.7% 15 (95% CI, 52.7% to 60.6%) of cases. Two studies, which included only parenteral antibiotic use, showed improvement in 52.9% 6 (95% CI, 27.8% to 77.0%) and 75.9% 7 (95% CI, 56.5% to 89.7%) of cases. Three studies reported symptom response for specific infection sites. 7, 15, 16 Of these, two studies reported symptomatic improvement of 60% to 92% for urinary tract infections (UTIs) and 0% to 53% for respiratory tract infections. 15, 16 There was no observed symptom improvement among patients with bacteremia. 15, 16 In both studies, antibiotics were administered orally except in bacteremia cases where parenteral administration was used. 15, 16 The third study, by Clayton and colleagues, also observed site-specific infections, but we determined that the proportions of patients whose symptoms improved were unreliable due to the inclusion of patients with unknown outcome status in the calculations. 7 Studies including fever as an indication for antimicrobial use reported fever resolution in 47.9% 8 (95% CI, 37.7% to 58.3%) and 54.4% 9 (95% CI, 42.8% to 65.7%) of cases. In contrast, fever resolution occurred in 1 of 14 (7.1%) cases not treated with antimicrobial therapy. 9 
Discussion
We systematically reviewed the medical literature to summarize data regarding antimicrobial use for symptom management in palliative and hospice care. We identified eight studies that measured symptom improvement following antimicrobial therapy, but no study included a comparison group of patients not receiving antimicrobial therapy. Furthermore, heterogeneity in the measurement of both antimicrobial use and symptom reduction limit the utility of these data to clarify the benefits of antimicrobial therapy in this population.
The lack of comparison between patients who did and did not receive antimicrobial therapy is an important weakness of the existing literature, and as a result, we lack an accurate estimate of the effectiveness antimicrobial therapy. At present, there is not equipoise to consider a randomized study for this association. Rather, a cohort study comparing outcomes between patients with infective symptoms who received antimicrobial therapy to patients who did not receive antimicrobial therapy is possible and may address the weaknesses of previous studies. Furthermore, most studies utilized subjective clinical notes to quantify or, more often, qualify patient symptoms rather than applying strict definitions of improvement or utilizing validated symptom measurement tools. Only one study used a validated method of symptom assessment, measured before and after initiation of antimicrobial theory; 13 and two studies used only resolution of fever as the criterion for improvement. 8, 9 Clinical assessment of changes in symptom burden is highly subjective and is likely neither a sensitive nor specific method to identify infection-associated symptom improvement. 17 In addition, it may not be possible to elucidate changes in infection-associated symptoms from other symptoms associated with the patient's underlying disease trajectory. It is also possible that medications other than antimicrobial therapy administered to treat symptoms in these patients may mask the independent effect of antimicrobial therapy on infection-associated symptoms. However, these effects can be studied using validated measures of symptom burden and by adjustment for confounding variables. We did not identify a single study that adjusted for the potential confounding effects of underlying disease or other drug exposures in evaluating symptom improvement. These methodological limitations support the need for prospective studies using a systematic process and validated measures for assessing symptoms.
In addition to the lack of specificity to attribute symptoms to infectious causes, most infections in this patient population are not formally diagnosed, especially in hospice care. 3 In our study of antibiotic prescribing in a nationwide sample of hospice patients in the last week of life, only 15% of patients who received antibiotics had a potential infectious indication documented in the patient's medical chart. 3 While our estimate and that of another recent study 18 likely underrepresent the true frequency of suspected infections, they shed little light on the indications for antimicrobial use in this population. The Healthcare Infection Control Practices Advisory Committee (HICPAC) has proposed definitions for infections in home-based hospice care, but to our knowledge these have not been applied in research studies. 19 In addition, Stone and colleagues recently updated definitions for infections in longterm care facilities. 20 It may be reasonable to consider these definitions or a similar approach when identifying suspected infections in residential hospice and palliative care populations. Furthermore, some infections, e.g., urinary tract infections or oral candidiasis may be more likely to improve symptomatically with antimicrobial therapy compared to other infections. In the studies that stratified results by infection site, greater improvement was observed in patients with urinary tract infections compared to other infection sites. 7, 15, 16 This study was limited by not including studies published in languages other than English. In addition, systematic reviews are susceptible to publication bias in that studies reporting a positive association between antimicrobial use and symptom reduction may be more likely to be submitted and accepted for publication compared to studies suggesting little or no benefit. We did not assess the potential for publication bias using funnel plots due to the limited number of studies identified. A recent review suggests that these assessments are not informative when the number of studies identified is less than 10. 21 The results of this study reaffirm the need for high-quality research in this area. Specifically needed are prospective studies that use robust measures of symptom improvement and account for important confounders such as concurrent symptom management strategies. Observational studies comparing patients who receive antimicrobial therapy with those who do not could employ propensity score matching to control for differences between the treated and untreated groups, especially confounding by indication. Finally, future studies need to be scrupulous about measuring adverse effects of antimicrobial therapy. Potential adverse events such as opportunistic Clostridium difficile infections and drug side effects are an important consideration when deciding to use antimicrobial therapy and may carry equal weight to any potential benefits of antimicrobial therapy in reducing symptom burden.
In conclusion, antimicrobial use is prevalent in hospice and palliative care patients, but existing research has not clarified the benefits of antimicrobial use for symptom improvement in this population. This study has identified the limitations of previous studies and presents opportunities for future research in this area. These studies are essential to improve the evidence base for the decision to use antimicrobial therapy and to assess the risks and benefits of this decision in this vulnerable population.
